<DOC>
	<DOCNO>NCT00119418</DOCNO>
	<brief_summary>This study test see TU 025 Keishi Bukuryo Gan reduce frequency severity hot flash post-menopausal American woman . This study also estimate best dose amount determine common short-term side effect risk .</brief_summary>
	<brief_title>TU 025 Keishi Bukuryo Gan Post-menopausal Hot Flash Management</brief_title>
	<detailed_description>Menopause natural transition woman 's hormonal state associate cessation ovulation menstruation . For approximately 80 % peri-menopausal woman , menopause may define experience uncomfortable symptom hot flash , night sweat , dyspareunia , urinary frequency , sleep disturbance , fatigue , depression anxiety . Hot flash common complaint perimenopausal postmenopausal Western woman . Approximately 10-20 % postmenopausal woman find symptoms nearly intolerable . Nearly one-third postmenopausal woman experience disruptive hot flash 5 year natural menopause approximately 20 % experience hot flash 15 year . Menopause understand estrogen deficiency state woman place great risk osteoporosis , colon cancer heart disease . For symptom management , well disease prevention , medical response 20 year hormone replacement therapy ( HRT ) . In recent year , many 38 % US woman age 50 74 year use HRT . For menopause hormone therapy , 2005 , counsel patient evidence-based perspective mean inform patient significantly increase risk dementia , breast cancer , endometrial cancer , venous thromboembolism gallbladder disease . Additionally , physician must also state hormone therapy increase risk cardiovascular event ( heart attack stroke ) woman without pre-existing heart disease . Furthermore , well-done study demonstrate hormone therapy enhance health-related quality life . For reason , great interest non-hormonal alternative menopausal hot flash management . The current standard care , base control clinical trial woman breast cancer , use SSRI anti-depressants venlafaxine . However , many woman seek option . In Japan , TJ25 Keishi Bukuryo Gan lead non-hormonal prescription agent management menopausal hot flash . However , clinical data exist effectiveness American woman . This pilot phase II clinical study estimate effectiveness TU-25 Keishi Bukuryo Gan reduction severity frequency hot flash healthy postmenopausal American woman . This study also estimate best dose determine common short-term side effect risk .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<criteria>Postmenopausal woman age 4558 adequate hot flash frequency severity score . Postmenopause define amenorrhea least 12 month , posthysterectomy one year folliclestimulating hormone level great equal 40 mIU/mL estradiol ( E2 ) level less equal 20 pg/mL , great two month post oophorectomy . All subject must date pap mammogram screen US Preventative Services Taskforce Guidelines length trial . All subject prescription medication need approval prescribe physician participation trial . Concurrent hot flash therapy ( prescription medication include hormone , antidepressant , SERMs , gabapentin counter supplement ) Moderately severe disease state ( ) diseases affect absorption/metabolism , diseases mimic menopausal hot flash . Inability swallow vitamin size pill Beck depression inventory score great 11 Greater 10 cigarette per day Abnormal liver function Treated untreated hypertension great 160/90 . BMI great 36 Inability give consent commit length trial Known hypersensitivity ingredient Physician judgment</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>58 Years</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>hot flash</keyword>
	<keyword>menopause</keyword>
	<keyword>herbal medicine</keyword>
	<keyword>kampo</keyword>
	<keyword>alternative medicine</keyword>
</DOC>